Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79285 | 1.00 | LTA4H (0.39) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL11787675 | 0.97 | LTA4H (0.38) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL9320360 | 0.97 | LTA4H (0.38) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL522366 | 0.97 | LTA4H (0.37) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL3429371 | 0.95 | OPRM1 (0.35) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL11209044 | 0.91 | LTA4H (0.36) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL4383611 | 0.89 | LTA4H (0.35) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL3431246 | 0.89 | LTA4H (0.35) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL3426360 | 0.88 | LTA4H (0.34) | LTA4HCYP2D6CYP2C9HSD17B10TSHR | |
| SCHEMBL22749520 | 0.87 | MAPT (0.42) | LTA4HCYP2D6CYP2C9HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973512-B1 | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-0970046-B1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-12-12 | — | — | US | disclosed |
| US-6441023-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-03-14 | — | — | US | disclosed |
| US-6342508-B1 | ENZYME INHIBITORS FOR PROTECTION OF CONNECTIVE TISSUES | AMERICAN CYANAMID COMPANY | 2002-01-29 | — | — | US | disclosed |
| US-6331563-B1 | LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE | WYETH HOLDINGS CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6288086-B1 | COMPOUNDS SUCH AS 1-METHYL-4-(4-BUTOXY-BENZENESULFONYL) -PIPERIDINE-4-CARBOXYLIC ACID HYDROXYAMIDE USED TO TREAT ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, ETC.; LOW MOLECULAR WEIGHT AND NON-PEPTIDAL | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| US-6197791-B1 | ANTIARTHRITIC AGENTS; WOUND HEALING AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6172057-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-01-09 | — | — | US | disclosed |
| EP-1054858-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-29 | — | — | EP | disclosed |
| EP-0973512-A1 | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| EP-0970046-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1998038163-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998037877-A1 | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
| US-4068077-A | Manufacture of N-substituted tetrahydro-1,4-oxazines | BASF AKTIENGESELLSCHAFT (DT) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | LTA4H 921/4885CYP2D6 1899/4885CYP2C9 2518/4885 |
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | LTA4H 889/4885CYP2D6 1665/4885CYP2C9 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.